Tengsheng Pharmaceutical Co., Ltd. (02137) released groundbreaking new data from the ENSURE II phase study at the 2025 AASLD meeting.

Zhtng Cijng APP news, Tngshngb yo-B (02137) announced that the company has released the follow-up results of the ENSURE II Phase 4 study at 24 weeks after the end of treatment (EOT). These latest data were presented at the American Association for the Study of Liver Diseases (AASLD) Liver Disease Conference held in Washington, D.C. from November 7th to 11th, 2025, and have been simultaneously published in the journal "Nature Medicine".